Ophthalmology 360
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Photo Contest
    • Industry Council
    • Advisory Board

What are you looking for?

  • Anterior Segment
  • Cataract
  • Cornea and External Disease
  • Diabetic Macular Edema
  • Dry Eye
  • Early Onset Cataracts
  • Exclusives
  • General
  • Geographic Atrophy
  • Glaucoma
  • Industry News
  • Inherited Retinal Disease
  • IOLs
  • Neurotrophic Keratitis
  • Ocular Surface Disease
  • Oculoplastics
  • Optometry
  • Pediatrics
  • Practice Management
  • Presbyopia
  • Refractive Surgery/Vision Correction
  • Residents & Young Ophthalmologists
  • Retina
  • Retina Care 360
  • Retinopathy of Prematurity
  • Spotlight Series
  • The Interventional Glaucoma Project
  • The Ophthalmic Project
  • Trending Topics
2nd Annual Photo Contest - Enter Here!
Ophthalmology 360
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Photo Contest
    • Industry Council
    • Advisory Board
Home > Dry Eye > Preservative-free lubricants linked to improved dry eye symptoms in real-world study
  • Dry Eye

Preservative-free lubricants linked to improved dry eye symptoms in real-world study

Kelsey Moroz

Key Takeaways

  1. Preservative-free lubricant drops were associated with significant improvements in dry eye symptoms over 6 months, with OSDI scores declining from 33.9 at baseline to 16.8 at month 6 (P < 0.001).
  2. Tear film stability, corneal staining, and vision-related quality of life improved during treatment, although the single-arm study design limits interpretation of the findings.

Preservative-free lubricant eye drops are associated with significant improvements in symptoms and ocular surface measures in adults with mild-to-moderate dry eye disease (DED), according to a study.

The ENRICHED-PF trial enrolled 120 adults with DED who were treated with preservative-free propylene glycol 0.3%/polyethylene glycol 0.4% drops for 6 months. Investigators assessed effectiveness, adherence, and safety under real-world clinical conditions using longitudinal analyses.

Median Ocular Surface Disease Index (OSDI) score at baseline was 31.2. Model-based analyses showed mean OSDI scores declined from 33.9 at baseline to 23.1 at 3 months and 16.8 at 6 months (P < 0.001). A clinically meaningful response, defined as at least a 10-point improvement in OSDI score, was achieved by 65.4% of the modified intention-to-treat population and 58% of the per-protocol population.

Over the study period tear break-up time increased, corneal staining scores decreased, and National Eye Institute Visual Function Questionnaire-25 composite scores improved by 8.9±3.1 points (P < 0.001). Schirmer I test values remained stable.

Because the study did not include a control group and some patients were lost to follow-up, the researchers said additional comparative studies are needed to confirm the findings.

Reference
Bustamante-Arias A, Satizabal-García JE, Pino-Murcia D, et al. ENRICHED trial of preservative-free lubricants in dry eye disease. Sci Rep;doi: 10.1038/s41598-026-50779-6. Epub ahead of print. PMID: 42251079.

Share

Related Content

  • Dry Eye

Probiotic use tied to lower risk of primary open-angle glaucoma in adults with dry eye

  • Dry Eye

Statin use linked to a small increase in dry eye disease risk

  • Dry Eye

Analysis of FDA reports reveals widespread ocular adverse events linked to antidepressants

  • Cataract

Optimizing cataract surgery outcomes through dry eye management

  • Dry Eye

Spotlight on LACRIFILL®

  • Conference Roundup

If your patient has recurrent chalazia, consider co-occurring Demodex blepharitis

Share

Editor's Picks

  • Neurotrophic Keratitis

Topical insulin shows real-world benefit in neurotrophic keratopathy

  • Retina

GLP-1 RAs have protective effects against AMD

  • Retina

Four-month injection intervals appear safe for long-term stable nAMD

Advisory Board

Saad Ahmad, MD

Ahmad A. Aref, MD, MBA

Roomasa Channa, MD

David Chow, MD, FRCS(C)

Sally L. Baxter, MD, MSc

Neel R. Desai, MD

Nadia Haqqie, MD

Simon Fung, MD, FRCOphth

Sumit Garg, MD

Ross Lakhanpal, MD, FACS

Sanjai Jalaj, MD

Anton Kolomeyer, MD, PhD

Shan Lin, MD

Steven R. Sarkisian, Jr., MD

See All
Ophthalmology 360

Ophthalmology 360® is a dynamic digital platform dedicated to advancing the field of eye care.

Get to Know Us

  • Home
  • About Us
  • Media Partners
  • Advertising Policy
  • Our Advisory Board

Sign up for our Newsletter

Sign up for our Newsletter to get our newest articles instantly!

  • Privacy Policy
  • Advertising Policy
  • Medical Disclaimer
IHM Logo

2026 Ophthalmology 360 is a trademark of International Healthcare Media, LLC. All rights reserved

  • MedJournal360 Icon
  • RareDisease360 Icon
  • MyHero360 Icon
  • Optometry360 Icon
  • Ophtalmology360 Icon